Background Anti‐tumour necrosis factor (anti‐TNF) monoclonal antibodies have shown
efficacy in inflammatory bowel diseases (IBD). As these therapies lose patent protection …

Background Biosimilars of anti‐tumour necrosis factor (TNF)‐α agents have now become
clinically available for the treatment of inflammatory bowel diseases (IBD). Aim To perform a …

Background Biological therapies represent a fundamental innovation for the management of
inflammatory bowel diseases (IBD). However, many biological originators have reached, or …

Background: Anti-tumor necrosis factor (anti-TNF) monoclonal antibodies have
revolutionized the treatment of inflammatory bowel diseases (IBD). However, because of …

A biosimilar is a copy of an approved biological medicine whose patent protections have
expired. Biosimilars of antibodies to tumour necrosis factor α (TNFα) are becoming important …

Introduction: Biological therapies have revolutionized the treatment of inflammatory bowel
diseases (IBD) in the last two decades. Though biological drugs are effective, their use is …

The introduction of biological therapies, particularly anti-TNFα agents, has revolutionized the
management of inflammatory bowel disease in those cases which are refractory to …

Abstract Background and Aim The biosimilar of infliximab, CT‐P13, has recently been
shown to be equivalent to infliximab in both efficacy and safety in the treatment of …

Introduction of biological therapies have led to dramatic changes in the management of
debilitating immune-mediated inflammatory bowel diseases (IBD) including ulcerative colitis …

Background: Anti-tumour necrosis factor-alpha (anti-TNF) antagonists have been the
mainstay in the treatment of inflammatory bowel diseases (IBDs) for over 20 years …